NCT01759511 - Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 18, 2012

Primary Completion Date

February 19, 2016

Study Completion Date

February 19, 2016

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG

Simtuzumab

200 mg/mL administered intravenously biweekly (per original protocol) or 125 mg/mL self-administered subcutaneously every 7 ± 2 days (per protocol amendment 1)

Trial Locations (6)

15213

University of Pittsburgh Medical Center, Pittsburgh

29425

Medical University of South Carolina, Charleston

37232

Vanderbilt University Medical Center, Nashville

85012

Arizona Pulmonary Specialists, Ltd., Scottsdale

90095

University of California, Los Angeles

94305

Stanford University Medical Center, Stanford